The Trip Report

#38 Hailey Gilmore: The Complexity of Psychedelic Science

Dec 20, 2024

Hailey Gilmore, a public health scientist and founder of Luminous Research Consulting, delves into the intricate world of psychedelic therapy. She discusses the regulatory challenges of introducing MDMA-assisted therapy to the market, navigating complex legal landscapes, and the role politics play in shaping policy. Hailey also draws fascinating parallels between HIV research and psychedelics, highlighting innovative treatment pathways. With a cautious yet optimistic lens, she explores the future of psychedelic science and its potential to revolutionize mental health care.

01:02:05

Creator website

Episode guests

Hailey Gilmore

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Navigating the logistical hurdles of FDA approvals and state regulations is essential for bringing MDMA-assisted therapy to market.

The integration of psychedelic therapies into healthcare mirrors past HIV therapy challenges, highlighting the need for clinician training and insurance alignment.

Smaller clinics may implement psychedelic therapies more rapidly than larger institutions due to their agility, despite larger facilities offering comprehensive care.

Deep dives

Logistical Hurdles in Psychedelic Therapy

Bringing MDMA-assisted therapy to market involves navigating complex logistical hurdles, including securing FDA approvals and addressing state-by-state legislative processes. The intricate interplay between insurance coverage, healthcare institutions, and drug scheduling significantly influences the accessibility of psychedelic therapies. As regulatory environments evolve, these logistical concerns remain critical to the effective rollout of innovative treatments. The experience of previous therapies, such as HIV-related medications, provides important lessons on overcoming these barriers.

Intro

3min

Navigating MDMA-Assisted Therapy and Legislation

5min

Journey Through Public Health and Psychedelics

18min

Navigating MDMA Therapy Regulations

19min

Political Shifts and Psychedelic Policy: A New Health Agenda

3min

Navigating Psychedelic Therapy and FDA Regulations

12min

Exploring the Future of Psychedelic Therapy

2min

Welcome back to The Trip Report Podcast, a production of Beckley Waves.

Today, I am speaking with Hailey Gilmore, the former Medical Science Liason at MAPS PBC, Lykos Therapeutics, and founder of Luminous Research Consulting

Hailey joined MAPS in 2020, where she spearheaded their investigator-initiated trials (IIT) program, overseeing how MDMA-assisted therapy could address diverse clinical indications. Her role involved navigating complex regulatory landscapes, establishing protocols, and engaging with researchers worldwide.

Today, as the founder of Luminous Research she leverages her expertise to guide organizations in bringing psychedelics and other innovative therapies to market.

Hailey is a public health scientist with a master’s degree in epidemiology and biostatistics from UC Berkeley. She has spent over 15 years in clinical trial management, initially in the HIV prevention field, where she contributed to groundbreaking studies such as the efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.

This conversation is a masterclass in understanding psychedelic therapy development's nuanced challenges and opportunities.

Here’s what we cover:

* The Landscape of Psychedelic Therapy: Hailey breaks down the logistical hurdles of bringing MDMA-assisted therapy to market, from FDA approvals to state-by-state legislative processes and the complex interplay of insurance, healthcare institutions, and drug rescheduling.

* Insights from HIV Research: Drawing parallels with PrEP’s rollout, Hailey provides a framework for how psychedelics might navigate similar adoption barriers, including clinician training, insurance buy-in, and the balancing act between small, agile clinics and large academic centers.

* The Role of Smaller Clinics vs. Academic Institutions: She reflects on how smaller clinics might be better positioned to implement MDMA-assisted therapy quickly, given their flexibility, while larger institutions struggle to turn their metaphorical cruise ships.

* Systemic Challenges in the Psychedelic Field: From the intricacies of DEA licensing to the limitations of current research funding, Hailey outlines the systemic barriers that continue to slow progress in this field.

* Optimism Amid Complexity: Despite the delays in MDMA-assisted therapy’s approval, Hailey believes that public-private partnerships and innovative trial designs could unlock new opportunities for psychedelic research and implementation.

Finally, we explore the potential impact of Robert F. Kennedy Jr.'s potential appointment as Secretary of Health and Human Services in the Trump administration. Could this mark a turning point for federal policy on psychedelics? Hailey weighs the possibilities and shares her vision for how public health could guide this evolving conversation.

And now, I bring you my conversation with Hailey Gilmore.

Listen to the episode on Substack, Spotify, Google or Apple.

Credits:

* Hosted by Zach Haigney

* Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari

* Find us at thetripreport.com

* Follow us on Instagram, Twitter, LinkedIn and YouTube

Theme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com